Not certain. only 2% of OvCa are due to lynch syndrome. Survival in known
lynch may be better because it is often diagnosed earlier stage https://t.co/cW5LTrcJKz
This algorithm is experimental but we hope to validate it in the study and also assess the view of the public of population risk screening https://t.co/7TlbhfbXFW
We developed an algorithm to help determine persons risk of OvCa & Breast Ca by analysing genetic differences in saliva & knowing family Hx. https://t.co/7TlbhfbXFW
We hope in the future to have screening test to detect ovarian cancer early & to use them in BRCA+ people and other at high risk of OvCa https://t.co/2rtVn4tqw3
Primary prevention measures such are prophylactic surgery to remove ovaries and fallopian tubes at the appropriate age will help reduce risk https://t.co/2rtVn4tqw3
not clear but not yet- still no good early screening test for OvCa. OCA funded research at Imperial e.g. PROGRESS, is looking at this https://t.co/2rtVn4tqw3
recent results from trials show that some patients with BRCA+ OvCa can benefit for many years from PARP inhibitors. Unfortunately not all https://t.co/khcnyWBx2a
If BRCA+ & eligible for olaparib then this would be best option. Immunotherapy still experimental and available in certain clinical trials https://t.co/khcnyWBx2a
If further relapse after 6 months from last platinum & carboplatin still effective then olaparib would be available as maintenance on NHS https://t.co/gEbGGaV1gl
But PARP inhibitors are used as maintenance treatment after carboplatin in BRCA+ OvCa in certain circumstances. Discuss with your oncologist https://t.co/i9D6o6xCHq
carboplatin is often very effective in ovarian cancer and in BRCA+. Keep going with carboplatin if effective. T-cell still experimental https://t.co/aXrEMJ5BjO
Not abnormal. OCA & our team are working to spread the message to GPs and the public about BRCA to help prevent cancer and diagnose earlier https://t.co/AE44RBR8AU
Probably because when BRCA is abnormal in cancer cells, chemotherapy & PARP inhibitors are more effective. Other reasons not yet known https://t.co/gGlety0cni
Sometimes BRCA+ cancer cells become resistant to PARP inhibitors. We don't yet know if giving a different PARP inh in this situation helps https://t.co/7ptRbuwWa3
Available via the CDF in patients just diagnosed with OvCa who are having their first chemotherapy but depends on the stage of the OvCA. https://t.co/Jb831UcAu3
With the newer drugs on the horizon this may change. A recent study shows for patients surviving for many years, this effect may be lost https://t.co/V4tJzGMSI9